Product Name: HER2 CISH pharmDx Kit Catalog/Model number: SK109, lot 20000910 Product Usage: For in vitro diagnostic use. HER2 CISH pharmDx Kit is intended for dual-color chromogenic visualization of signals achieved with directly labeled in situ hybridization probes targeting the HER2 gene and centromeric region of chromosome 17. The kit is designed to quantitatively determine HER2 gene status in formalin-fixed, paraffin-embedded breast cancer tissue specimens. Red and blue chromogenic signals are generated on the same tissue section for evaluation under bright field microscopy. The CISH procedure is automated using Dako Autostainer instruments. HER2 CISH pharmDx Kit is indicated as an aid in the assessment of patients for whom Herceptin (trastuzumab) treatment is being considered. Results from the HER2 CISH pharmDx Kit are intended for use as an adjunct to the clinicopathologic information currently used for estimating prognosis in stage II, node-positive breast cancer patients.
Publicado el 5 de marzo de 2014 · Inicio del retiro: 21 de enero de 2014
Resumen
FDA registra el retiro Z-1093-2014 de dispositivos médicos de Clase II, publicado el 5 de marzo de 2014 e iniciado el 21 de enero de 2014. Empresa responsable: Dako North America Inc.; Estado: Finalizado; Cantidad reportada: 49; Lote: Catalog/Model number: SK109, lot 20000910. Shelf Life: 10 months when stored at 2-8 ¿C. Expiration Date: 2014 June 30. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Dako has initiated a recall of HER2 CISH pharmDxTM Kit because weak red signals have been observed.
Qué hacer
Voluntary: Firm initiated · E-Mail
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Dako North America Inc.
- Distribuidor
- Worldwide Distribution - USA Nationwide and in the country of Chile.
- Lote
- Catalog/Model number: SK109, lot 20000910. Shelf Life: 10 months when stored at 2-8 ¿C. Expiration Date: 2014 June 30.
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDADako Autostainer Link 48 with software version Dako Link 4.0.3, Model No. AS480 Product Usage: For in vitro1 de octubre de 2014
- FDA00434811113, REF I4348-111-13 Zimmer Trabecular Metal Shoulder Humeral Stem 48 Degrees 11 mm Stem Diameter 1305 de marzo de 2014
- FDANovaSure Impedance Controlled Endometrial Ablation System Radiofrequency Controller, Model Number: 71978-0015 de marzo de 2014
- FDAThe FOCUS is a microprocessor controlled intra-oral x-ray unit with a Load Matching Frequency (LMF) DC5 de marzo de 2014
- FDACSI, Diamondback 360 Coronary Orbital Atherectomy System, Part Number 70058-02, Model Number DBEC-125 Product5 de marzo de 2014
- FDAPT Link Waterbath, Model#PT100. Lab Vision PT Module Plus provides an automated standarized alternative to21 de noviembre de 2012
Preguntas sobre este retiro
¿Product Name: HER2 CISH pharmDx Kit Catalog/Model number: SK109, lot 20000910 Product Usage: For in vitro diagnostic use. HER2 CISH pharmDx Kit is intended for dual-color chromogenic visualization of signals achieved with directly labeled in situ hybridization probes targeting the HER2 gene and centromeric region of chromosome 17. The kit is designed to quantitatively determine HER2 gene status in formalin-fixed, paraffin-embedded breast cancer tissue specimens. Red and blue chromogenic signals are generated on the same tissue section for evaluation under bright field microscopy. The CISH procedure is automated using Dako Autostainer instruments. HER2 CISH pharmDx Kit is indicated as an aid in the assessment of patients for whom Herceptin (trastuzumab) treatment is being considered. Results from the HER2 CISH pharmDx Kit are intended for use as an adjunct to the clinicopathologic information currently used for estimating prognosis in stage II, node-positive breast cancer patients. fue retirado del mercado?
Sí. FDA publicó el retiro Z-1093-2014 el 5 de marzo de 2014. Peligro reportado: Dako has initiated a recall of HER2 CISH pharmDxTM Kit because weak red signals have been observed.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · E-Mail